DK0768886T3 - Endothelforingseffekter og behandling af vasospastiske lidelser - Google Patents

Endothelforingseffekter og behandling af vasospastiske lidelser

Info

Publication number
DK0768886T3
DK0768886T3 DK96911890T DK96911890T DK0768886T3 DK 0768886 T3 DK0768886 T3 DK 0768886T3 DK 96911890 T DK96911890 T DK 96911890T DK 96911890 T DK96911890 T DK 96911890T DK 0768886 T3 DK0768886 T3 DK 0768886T3
Authority
DK
Denmark
Prior art keywords
patient
treatment
vasospastic disorders
endothelial lining
aliquot
Prior art date
Application number
DK96911890T
Other languages
Danish (da)
English (en)
Inventor
Anthony Ernest Bolton
Ernest Davidson Cooke
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9509197.1A external-priority patent/GB9509197D0/en
Priority claimed from GBGB9522475.4A external-priority patent/GB9522475D0/en
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of DK0768886T3 publication Critical patent/DK0768886T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Developmental Biology & Embryology (AREA)
  • Cardiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
DK96911890T 1995-05-05 1996-05-03 Endothelforingseffekter og behandling af vasospastiske lidelser DK0768886T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9509197.1A GB9509197D0 (en) 1995-05-05 1995-05-05 Endothelial lining effects
GBGB9522475.4A GB9522475D0 (en) 1995-11-02 1995-11-02 Treatment of raynauds phenomenon
PCT/CA1996/000282 WO1996034613A1 (en) 1995-05-05 1996-05-03 Endothelial lining effects and treatment of vasospastic disorders

Publications (1)

Publication Number Publication Date
DK0768886T3 true DK0768886T3 (da) 2003-12-01

Family

ID=26306991

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96911890T DK0768886T3 (da) 1995-05-05 1996-05-03 Endothelforingseffekter og behandling af vasospastiske lidelser

Country Status (11)

Country Link
EP (1) EP0768886B1 (de)
JP (1) JPH10506636A (de)
AT (1) ATE246929T1 (de)
AU (1) AU721530B2 (de)
CA (1) CA2194485C (de)
DE (1) DE69629436T2 (de)
DK (1) DK0768886T3 (de)
ES (1) ES2205026T3 (de)
NZ (1) NZ306395A (de)
PT (1) PT768886E (de)
WO (1) WO1996034613A1 (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6669965B2 (en) 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
CA2206180A1 (en) * 1997-05-27 1998-11-27 Vasogen Inc. Treatment of chronic post-traumatic pain syndromes
NZ503770A (en) * 1997-09-12 2002-10-25 Vasogen Ireland Ltd Treatment of stress and associated symptoms by stressing blood cells and re-introducing them into the body
US6432399B1 (en) 1997-09-12 2002-08-13 Vasogen Ireland Limited Treatment of stress and preconditioning against stress
US6264646B1 (en) 1998-11-13 2001-07-24 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
PT1146885E (pt) * 1999-01-12 2003-10-31 Vasogen Ireland Ltd Pre-condicionamento contra a morte celular
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
DK1214037T3 (da) * 1999-09-16 2004-08-02 Vasogen Ireland Ltd Apparat til konditionering af pattedyrsblod
ATE309807T1 (de) 1999-09-24 2005-12-15 Vasogen Ireland Ltd Zusammensetzung zur behandlung von atherosklerose,welche ein statin und ex-vivo behandeltes blut enthält
CA2309417A1 (en) 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5100378A (en) * 1989-06-09 1992-03-31 Neorx Corporation Enhancement of target cell localization of lymphoid cells
AU3506293A (en) * 1992-02-07 1993-09-03 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
CA2129630C (en) * 1992-02-07 2003-09-23 Anthony E. Bolton Method of increasing the concentration of nitric oxide in blood
EP0804550A4 (de) * 1994-01-27 1998-08-05 Cellcor Inc Die ex vivo aktivierung von immunzellen

Also Published As

Publication number Publication date
NZ306395A (en) 2000-02-28
DE69629436D1 (de) 2003-09-18
ATE246929T1 (de) 2003-08-15
DE69629436T2 (de) 2004-06-17
CA2194485C (en) 2001-09-18
AU721530B2 (en) 2000-07-06
EP0768886B1 (de) 2003-08-13
ES2205026T3 (es) 2004-05-01
CA2194485A1 (en) 1996-11-07
JPH10506636A (ja) 1998-06-30
EP0768886A1 (de) 1997-04-23
WO1996034613A1 (en) 1996-11-07
PT768886E (pt) 2003-12-31
AU5494496A (en) 1996-11-21

Similar Documents

Publication Publication Date Title
DK0920322T3 (da) Anvendelser af modificeret autologt blod til behandling af autoimmunitetssygdomme
ES2152483T3 (es) Aplicacion terapeutica en anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de celulas b.
ATE232396T1 (de) Oxydiertes thymosin beta 4
MY124091A (en) Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
ATE399553T1 (de) Pharmazeutische zusammensetzungen mit dextromethorphan und chinidin zur behandlung von neurologischen erkrankungen
ATE191506T1 (de) Gentherapeutische behandlung von gefässerkrankungen durch einen zellspezifischen, zellzyklusabhängigen wirkstoff
NO974275D0 (no) Fremgangsmåte for behandling av tumorer
ATE282425T1 (de) Verfahren zur behandlung von endothelialen verletzungen
PT768886E (pt) Efeitos de revestimento endotelial e tratamento de desordens vasospasticas
DK0661987T3 (da) Morphogeninduceret leverregeneration
DE69840913D1 (de) Divalent anti-t-zellen immuntoxinen und deren verwendung
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
DE60137146D1 (de) Fusionszellen und zytokin-zusammensetzungen zur behandlung von krankheiten
DK0841912T3 (da) 2-Aminocarbonyl-1,2-bis-(methylsulfonyl)-1-(substituerede)-hydraziner med antitumor-virkning
AR004494A1 (es) Una celula util para el tratamiento del dolor, un metodo para producirla, un organo bioartificial de la comprende y un metodo para preparar dicho organobioartificial
DE69533873D1 (de) Krebstherapie mit lymphotoxin
ES2036526T3 (es) Composiciones de interferon.
DK188680A (da) Fremgangsmaade til fremstilling af 6-substituerede 11-alkylenmorphantridiner
AR015956A1 (es) Composiciones de citoquinas oromucosales y usos de las mismas
TR199901385T2 (xx) Piperidin t�revleri.
MX9206135A (es) Metodos
UA39179C2 (uk) Фармацевтична композиція для лікування порушень серцевого ритму у великих ссавців та людей, спосіб її одержання та антиаритмічний лікарський засіб
DE69928407D1 (de) Ex vivo behandlung von allogenen und xenogenen t-zellen mit gp39-antagonisten
DE50305753D1 (de) Verfahren und mittel zur prävention, hemmung und therapie von krebserkrankungen
UA31903A (uk) Спосіб лікування хронічного неспецифічного простатиту